So erreichen Sie uns:

Gebührenfreie Rufnummer

Österreich, Tschechien, Frankreich, Deutschland, Italien, Polen, Spanien, Schweiz, Türkei und Großbritannien
+ 800 624 367 23
+ 800 MAGFORCE
Vereinigte Staaten, Kanada, Guam, Puerto Rico und US-Jungferninseln
+ 1 844 833 9623
Rufnummern weitere Länder
Nachricht schreiben
How to reach us:

Toll-free phone number

Austria, Czech Republic, France, Germany, Italy, Poland, Spain, Switzerland, Turkey and Great Britain
+ 800 624 367 23
+ 800 MAGFORCE
United States, Canada, Guam, Puerto Rico and US Virgin Islands
+ 1 844 833 9623
Phone numbers for other countries
Write a message

"Our goal: to develop an effective cancer therapy for the successful treatment of patients worldwide.”

Dr. Ben J. Lipps
CEO

"Our goal: to develop an effective cancer therapy for the successful treatment of patients worldwide.”

Dr. Ben J. Lipps
CEO
1997
Foundation
of our headquarters in Berlin
17
Quadrillions iron oxide nanoparticles
in just one milliliter of magnetic liquid
17
International patent families
approx. 100 individual patents and 65 patent applications
2011
Breakthrough
regulatory approval in the EU and first successful patient treatments

NanoTherm® fights the tumor from the inside.

MagForce is forging new paths in order to treat cancer successfully and gently: With NanoTherm® therapy, we have developed an innovative approach based on nanotechnology, which we want to make available to patients all over the world.

And we are getting closer and closer to this goal: NanoTherm® is the first and only nanotechnology-based therapy with European approval for the treatment of brain tumors. To date, over 100 patients have already been treated using our NanoTherm® therapy.

In Germany alone, five renowned clinics are already equipped with our patented equipment and are able to perform NanoTherm® therapies with increasing success. A treatment centre in Lublin, Poland is expected to open soon, while additional treatment centres in Italy and other European countries are planned.

A pivotal clinical study for the treatment of prostate cancer has been ongoing in the USA since July 2018 at selected specialised medical centres. Here, the goal is to obtain evidence for the effectiveness of the therapy, and to subsequently gain regulatory approval of this innovative and gentle herapy in the USA for the time being.

2018
April
In Washington and Texas, the ethics commissions (“Institutional Review Board”, IRB) gave two treatment centres in the USA - the University of Washington in Seattle and the Christus Santa Rosa Hospital in San Antonio - the green light to conduct the decisive clinical studies regarding the treatment’s effectiveness in prostate cancer.
February 2018
MagForce AG received approval from the American “Food and Drug Administration (FDA)” to conduct a clinical study using the NanoTherm® therapy for focal tumor ablation in prostate cancer with intermediate risk.
2017
November
MagForce AG participates in the annual conference of the “Society for NeuroOncology” in San Francisco, USA.
August 2017
MagForce AG announces the positive results of the 2017 annual general meeting.
June 2017
MagForce AG places a capital increase from authorized capital.
June 2017
MagForce AG presents itself at the “Long Night of the Sciences” in Berlin and demonstrated NanoTherm® live before an interested audience.
June 2017
On the occasion of the World Brain Tumor Day on the 8th of June, MagForce AG supports an event for brain tumor patients at the Münster University Hospital (UKM).
May 2017
MagForce organises the symposium, “Fokale Glioblastom-Behandlung” (Focal Glioblastoma Treatment), at the “World Federation of Neuro-Oncology Societies [WFNOS]” world conference, which is held every four years.
January 2017
In Amsterdam, MagForce presents NanoTherm® therapy for the treatment of brain tumors at the “European CanCer Organisation [ECCO]” conference.
2016
April
In Berlin, the commercial (i.e. conducted for non-study purposes) treatment of brain tumors using NanoTherm® therapy begins at the Vivantes Klinikum in Friedrichshain in cooperation with Charité-Universitätsmedizin.
2015
November
The first NanoActivator® in the USA is successfully put into operation in Seattle, Washington. This treatment terminal is initially used in a registration study for the focal thermal ablation of prostate cancer.
March 2015
The first treatment of a US-American patient with a brain tumor in Germany.
2014
November
Successful completion of growth financing round for MagForce USA, Inc. led by Mithril Capital Management.
January/May 2014
Pre-IDE meeting with the “Food and Drug Administration (FDA)” for the pre-submission of the NanoTherm® therapy for prostate cancer in January 2015 and submission of the application in May 2015.
May 2014
Pre-submission meeting at the “Food and Drug Administration (FDA)” for conducting a study using NanoTherm® therapy in the USA.
March 2014
The large-scale glioblastoma study MF1001 begins with the treatment of the first patients.
March 2014
Founding of the US-American subsidiary, MagForce USA, Inc., in order to introduce NanoTherm® therapy for the treatment of glioblastoma and prostate cancer in the USA.

The management board

The supervisory board

2018

April

In Washington und Texas geben die Ethikkommissionen („Institutional Review Board“, IRB) der beiden US-Behandlungszentren (Universität of Washington, Seattle, und Christus-Santa-Rosa-Hospital in San Antonio) grünes Licht für die Durchführung der klinischen Studien zur Wirksamkeit bei Prostatakrebs.

2018

Februar

MagForce AG erhält von der amerikanischen „Food and Drug Administration (FDA)“ die Genehmigung zur Durchführung einer klinischen Studie mit der NanoTherm® Therapie zur fokalen Tumorablation bei Prostatakrebs mit intermediärem Risiko.

2017

November

MagForce AG nimmt am Jahreskongress der “Society for NeuroOncology” in San Francisco, USA, teil.

2017

August

MagForce AG gibt die positiven Ergebnisse der Jahreshauptversammlung 2017 bekannt.

2017

Juni

MagForce AG platziert eine Kapitalerhöhung aus genehmigtem Kapital.

2017

Juni

Die MagForce AG präsentiert sich auf der „Langen Nacht der Wissenschaften“ in Berlin und demonstriert NanoTherm® live vor interessiertem Publikum.

2017

Juni

Anlässlich des internationalen Welthirntumortages am 8. Juni unterstützt die MagForce AG ein Event für Hirntumorpatienten des Universitätsklinikums Münster.

2017

Mai

MagForce veranstaltet das Symposium „Fokale Glioblastom-Behandlung“ auf dem alle vier Jahre stattfindenden Weltkongress der „World Federation of Neuro-Oncology Societies (WFNOS)“.

2017

Januar

In Amsterdam präsentiert MagForce die NanoTherm® Therapie zur Behandlung von Hirntumoren auf dem Kongress der „European CanCer Organisation (ECCO)“.                   

2016

April

In Berlin beginnt die kommerzielle (d.h. nicht zu Studienzwecken durchgeführte) Behandlung von Hirntumoren mit der NanoTherm® Therapie im Vivantes Klinikum Friedrichshain in Kooperation mit der Charité-Universitätsmedizin.

2015

November

Der erste NanoActivator® in den USA wird erfolgreich in Seattle, Washington, in Betrieb genommen. Dieses Behandlungsterminal wird zunächst in einer Registrierungsstudie zur fokalen thermalen Ablation von Prostatakrebs eingesetzt.

2015

März

Die erste Behandlung eines US-amerikanischen Patienten mit Gehirntumor in Deutschland.

2014

November

Erfolgreicher Abschluss einer Wachstumsfinanzierungsrunde für MagForce USA, Inc. unter der Führung von Mithril Capital Management.
                        

2014

Januar/Mai

Pre-IDE-Meeting mit der „Food and Drug Administration (FDA)“ zur Pre-Submission für die NanoTherm® Therapie für Prostatakrebs im Januar 2015 und Einreichung des Antrags.

2014

Mai

Pre-Submission Meeting bei der „Food and Drug Administration (FDA)“ für die Durchführung einer Studie mit der NanoTherm® Therapie in den USA.

2014

März

Die großangelegte Glioblastom-Studie MF1001 beginnt mit der Behandlung des ersten Patienten.

2014

März

Gründung der US-amerikanischen Tochtergesellschaft MagForce USA, Inc. für die Einführung der NanoTherm® Therapie zur Behandlung von Glioblastom und Prostatakrebs.